| Champion Iron Limited (CIA) ORDINARY FULLY PAID |
Materials |
$2,458 |
Half-Year Report
|
31 Oct 2024 8:26AM |
$5.890 |
$4.610 |
fallen by
21.73%
|
|
| Champion Iron Limited (CIA) ORDINARY FULLY PAID |
Materials |
$2,458 |
Investor Presentation Q2 FY2025
|
31 Oct 2024 8:26AM |
$5.890 |
$4.610 |
fallen by
21.73%
|
|
| Ryder Capital Limited (RYD) ORDINARY FULLY PAID |
Financials |
$112 |
Update - Notification of buy-back - RYD
|
31 Oct 2024 8:25AM |
$1.280 |
$1.380 |
risen by
7.81%
|
|
| Vinyl Group Ltd (VNL) ORDINARY FULLY PAID |
Information Technology |
$155 |
Change in substantial holding
|
31 Oct 2024 8:25AM |
$0.145 |
$0.115 |
fallen by
20.69%
|
|
| Dimerix Limited (DXB) ORDINARY FULLY PAID |
Health Care |
$321 |
Quarterly Appendix 4C and Activities Report
|
31 Oct 2024 8:24AM |
$0.405 |
$0.535 |
risen by
32.10%
|
|
DXB - Price-sensitive ASX Announcement
Full Release
Key Points
- Dimerix is developing DMX-200 for FSGS.
- 129 patients randomized in the ACTION3 clinical trial.
- Cash balance at the end of the quarter was AU$19.18 million.
- Strong partner interest in DMX-200 continues.
- Clinical recruitment across 17 countries is actively ongoing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vinyl Group Ltd (VNL) ORDINARY FULLY PAID |
Information Technology |
$155 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Oct 2024 8:24AM |
$0.145 |
$0.115 |
fallen by
20.69%
|
|
VNL - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenues grew $545K to a record $2.759M or 25% QoQ
- Company completed the acquisition of Mediaweek and Serenade Sound
- Announcement of a further acquisition of Funkified Events
- Backend changes to reduce the cost of Jaxsta infrastructure
- Launch of Vinyl.com into the UK
- Signed a two-year agreement to represent Songtradr's digital advertising assets
- Conversion of convertible note reduced debt by close to $1.6M
- Cash reserves decreased by $589K
- Successful option exercise brought in $1.8M to cover acquisition costs
- Focus on integration of acquisitions to improve margins
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| INOVIQ Ltd (IIQ) ORDINARY FULLY PAID |
Health Care |
$47 |
Quarterly Business Update and Appendix 4C - September 2024
|
31 Oct 2024 8:24AM |
$0.465 |
$0.420 |
fallen by
9.68%
|
|
IIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Progress in commercial, development, and corporate activities.
- NEURO-NET technology validated for isolating brain-derived exosomes.
- Ovarian Cancer Screening test biomarker validation study underway.
- CAR-NK exosome program expected to deliver in vitro data by December 2024.
- Mary Harney appointed as Non-Executive Director.
- Expansion of management team and establishment of Medical and Scientific Advisory Committee.
- Capital raise of $9.4 million completed.
- Cash balance of $10.024 million at 30 September 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brambles Limited (BXB) ORDINARY FULLY PAID |
Industrials |
$31,892 |
Update - Notification of buy-back - BXB
|
31 Oct 2024 8:24AM |
$18.300 |
$23.330 |
risen by
27.49%
|
|
| Champion Iron Limited (CIA) ORDINARY FULLY PAID |
Materials |
$2,458 |
Quarterly Activities Report - Q2 FY2025 Results
|
31 Oct 2024 8:24AM |
$5.890 |
$4.610 |
fallen by
21.73%
|
|
CIA - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly production of 3.2M wmt, sales of 3.3M dmt, revenue of $351M, EBITDA of $75M and EPS of $0.04
- Declares a dividend of $0.10 per ordinary share
- DRPF project advancing as planned for scheduled commissioning in H2/2025 with additional $65M invested this quarter
- Reported challenges including forest fires that impacted operations but also achieved record material mined and hauled
- No serious injuries or major environmental incidents reported during the quarter
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ironbark Capital Limited (IBC) ORDINARY FULLY PAID |
Financials |
$46 |
Update - Notification of buy-back - IBC
|
31 Oct 2024 8:23AM |
$0.460 |
$0.435 |
fallen by
5.43%
|
|
| Opthea Limited (OPT) ORDINARY FULLY PAID |
Health Care |
$739 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Oct 2024 8:23AM |
$0.840 |
$0.600 |
fallen by
28.57%
|
|
OPT - Price-sensitive ASX Announcement
Full Release
Key Points
- Leadership appointments strengthen medical and commercial capabilities.
- Successful completion of drug substance PPQ campaign validating sozinibercept manufacturing process.
- Opthea joined the S&P/ASX 300 Index.
- Presented findings at the 24th EURETINA Congress.
- Sozinibercept evaluated in two pivotal Phase 3 clinical trials for wet AMD.
- Cash balance of US$167.5 million at the end of the quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID |
Health Care |
$124 |
Proposed issue of securities - ATX
|
31 Oct 2024 8:23AM |
$0.135 |
$0.320 |
risen by
137.04%
|
|
| Frontier Digital Ventures Limited (FDV) ORDINARY FULLY PAID |
Communication Services |
$121 |
3Q 2024 Trading Update & Strategic Review
|
31 Oct 2024 8:23AM |
$0.515 |
$0.280 |
fallen by
45.63%
|
|
FDV - Price-sensitive ASX Announcement
Full Release
Key Points
- FDV reported A$83.4m revenue for the last twelve months to 3Q 2024, a 5% increase.
- EBITDA for the same period reached A$7.2m, showing a 14% rise.
- The 360 LATAM segment generated A$55.4m in revenue, a 12% increase.
- A strategic review has been initiated to maximize shareholder value focused on 360 LATAM.
- The current market valuation does not reflect the value of FDV's operating regions.
- FDV's revenue has shifted significantly to Latin America, with 66% of total revenue coming from there.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| G8 Education Limited (GEM) ORDINARY FULLY PAID |
Consumer Discretionary |
$694 |
Update - Notification of buy-back - GEM
|
31 Oct 2024 8:22AM |
$1.320 |
$0.900 |
fallen by
31.82%
|
|
| Altair Minerals Limited (ALR) ORDINARY FULLY PAID |
Materials |
$17 |
ALR September 2024 Quarterly Activities Report & Appendix 5B
|
31 Oct 2024 8:22AM |
$0.004 |
$0.004 |
risen by
14.29%
|
|
ALR - Price-sensitive ASX Announcement
Full Release
Key Points
- Assay results from Wee MacGregor project showed 18 samples over 1% copper and 9 samples over 1g/t gold.
- Surface sampling indicated exceptional grades of near surface copper and gold at Wee MacGregor.
- The Horse-Well Project is strategically located near BHP’s Oak Dam West discovery.
- Geophysical data from the Olympic Domain project is being reprocessed to identify new targets.
- Altair is evaluating opportunities in the resources sector and aims to generate value for shareholders.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alcidion Group Limited (ALC) ORDINARY FULLY PAID |
Health Care |
$148 |
Q1 FY25 Quarterly Activities Report and Appendix 4C
|
31 Oct 2024 8:22AM |
$0.052 |
$0.110 |
risen by
111.54%
|
|
ALC - Price-sensitive ASX Announcement
Full Release
Key Points
- New TCV sales of $5.2 million in Q1 FY25.
- Five-year contract signed with Hume Rural Health Alliance valued at $4.0 million.
- Expected revenue recognition of $2.0 million in FY25.
- Cash receipts of $6.3 million and operating cash outflow of $3.9 million.
- Targeting EBITDA positive for FY25 with breakeven revenue of approximately $36.0 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bio-Gene Technology Ltd (BGT) ORDINARY FULLY PAID |
Materials |
$5 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Oct 2024 8:22AM |
$0.058 |
$0.018 |
fallen by
68.97%
|
|
BGT - Price-sensitive ASX Announcement
Full Release
Key Points
- Collaboration with Envu to evaluate Flavocide for mosquito management.
- Successful pilot-scale production of Flavocide by Rallis India.
- Regulatory studies for Flavocide registration confirmed.
- Cash reserves decreased to $1.4 million.
- Plans for commercial-scale production post-regulatory approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Many Peaks Minerals Limited (MPK) ORDINARY FULLY PAID |
Materials |
$81 |
Quarterly Activities Report & Appendix 5B
|
31 Oct 2024 8:21AM |
$0.235 |
$0.770 |
risen by
227.66%
|
|
MPK - Price-sensitive ASX Announcement
Full Release
Key Points
- 5,000m air core drilling campaign targeting high-strain corridor at Odienné project.
- 8,810m of reconnaissance drilling at Odienné successfully delineated >16km of priority targets.
- Fully funded exploration campaigns through CY2025 with AU$6.8M cash at hand.
- Major acquisitions completed for four gold projects in Côte d'Ivoire totaling 1,919km2.
- Ferké gold project exploration work planned following successful auger drilling results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Boom Logistics Limited (BOL) ORDINARY FULLY PAID |
Industrials |
$56 |
Update - Notification of buy-back - BOL
|
31 Oct 2024 8:21AM |
$0.145 |
$1.365 |
risen by
841.38%
|
|
| Rimfire Pacific Mining Limited (RIM) ORDINARY FULLY PAID |
Materials |
$61 |
Investor Presentation - October 2024
|
31 Oct 2024 8:21AM |
$0.060 |
$0.024 |
fallen by
59.66%
|
|
| Mach7 Technologies Limited (M7T) ORDINARY FULLY PAID |
Health Care |
$84 |
Annual Report to Shareholders FY2024
|
31 Oct 2024 8:21AM |
$0.505 |
$0.358 |
fallen by
29.21%
|
|
| Critical Resources Limited (CRR) ORDINARY FULLY PAID |
Materials |
$11 |
Field Work Campaigns to Begin at Antimony Prospects
|
31 Oct 2024 8:21AM |
$0.008 |
$0.004 |
fallen by
50%
|
|
CRR - Price-sensitive ASX Announcement
Full Release
Key Points
- Field work campaigns to commence at Hillgrove South and Mayview prospects.
- Desktop studies confirmed historic antimony occurrences in the Halls Peak Project.
- Geological mapping and sampling programs will delineate drilling targets.
- The Mayview prospect is potentially a continuation of the Hillgrove Antimony-Gold system.
- Elevated antimony values recorded in stream sediment samples south of Hillgrove.
- Experienced geologists will conduct detailed surveys of historic antimony workings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Coventry Group Limited (CYG) ORDINARY FULLY PAID |
Industrials |
$89 |
Appointment of new Director - Rob Martino
|
31 Oct 2024 8:21AM |
$1.380 |
$0.745 |
fallen by
46.01%
|
|
| Lotus Resources Limited (LOT) ORDINARY FULLY PAID |
Energy |
$415 |
Share Purchase Plan - Letter to Shareholders and Booklet
|
31 Oct 2024 8:21AM |
$0.260 |
$0.175 |
fallen by
32.69%
|
|
| Mach7 Technologies Limited (M7T) ORDINARY FULLY PAID |
Health Care |
$84 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Oct 2024 8:21AM |
$0.505 |
$0.358 |
fallen by
29.21%
|
|
M7T - Price-sensitive ASX Announcement
Full Release
Key Points
- Mach7 Technologies Limited focuses on strategic investments to enhance product innovation and customer service.
- CARR was reported at A$27.5M as of 30 September 2024.
- The company aims for 15-25% growth in CARR and revenue in FY25.
- Mach7 holds cash reserves of A$21.9M with plans to be cash flow positive in FY25.
- Sales orders for Q1 FY25 amounted to A$2.2M, primarily from ARR-type sales.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
